Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer

Lung cancer is the leading cause of cancer-related deaths among men and women worldwide. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective therapies for advanced non-small-cell lung cancer (NSCLC) patients harbouring EGFR-activating mutations, but are not curative...

Full description

Bibliographic Details
Main Authors:	Celia Delahaye, Sarah Figarol, Anne Pradines, Gilles Favre, Julien Mazieres, Olivier Calvayrac
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Cancers
Subjects:	drug-tolerant persisters lung cancer targeted therapies EGFR-TKI
Online Access:	https://www.mdpi.com/2072-6694/14/11/2613

Similar Items

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023-12-01)

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
by: Houssein Chhouri, et al.
Published: (2023-01-01)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
by: Kamal Eltayeb, et al.
Published: (2022-01-01)

Novel mechanism of resistance to targeted therapies in lung cancer
by: Walter Wang, et al.
Published: (2019-01-01)

Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
by: Hao Liu, et al.
Published: (2022-11-01)

Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study
by: Kiran Munawar, et al.
Published: (2022-11-01)

Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
by: Dylan A. Farnsworth, et al.
Published: (2021-12-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
by: Min-Kyung Yeo, et al.
Published: (2022-06-01)

Prognostic Factors in Patients with Advanced Lung Adenocarcinoma Treated with Icotinib
by: ZHANG Hongbin, et al.
Published: (2022-11-01)

Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma
by: Mao X, et al.
Published: (2022-03-01)

New prognostic system specific for epidermal growth factor receptor-mutated lung cancer brain metastasis
by: Li-Hua Zhu, et al.
Published: (2023-03-01)

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
by: Qian Zhou, et al.
Published: (2023-03-01)

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
by: Chao-Ju Chen, et al.
Published: (2021-02-01)

Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
by: Pamela Soberanis Pina, et al.
Published: (2023-03-01)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
by: Ming-Hung Huang, PhD, et al.
Published: (2022-11-01)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
by: Shigetoshi Nishihara, et al.
Published: (2022-11-01)

Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer
by: Jingwei Li, et al.
Published: (2022-09-01)

Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature
by: Ahmed Abdalhadi, et al.
Published: (2024-02-01)

Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI - Analysis of 2 Cases
by: Meirong LIU, et al.
Published: (2019-01-01)

Effects of 17-DMAG on Non-small Cell Lung Cancer Cell Lines A549 and H1975 Being Resistant to EGFR-TKI
by: Lei ZHAO, et al.
Published: (2014-11-01)

Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
by: Mu F, et al.
Published: (2023-04-01)

Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance
by: Maicol Mancini, et al.
Published: (2021-07-01)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in <i>EGFR</i>-Mutated NSCLC
by: Keigo Kobayashi, et al.
Published: (2023-02-01)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced <i>EGFR</i>-Mutant Lung Adenocarcinoma
by: Po-Hsin Lee, et al.
Published: (2022-07-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-03-01)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
by: Eric Santoni-Rugiu, et al.
Published: (2019-07-01)

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes
by: Lorraine Dalens, et al.
Published: (2023-07-01)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer
by: Sutpirat Moonmuang, et al.
Published: (2023-03-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
by: Jacqueline V. Aredo, et al.
Published: (2022-01-01)

Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin
by: Kuo-Yen Huang, et al.
Published: (2021-08-01)

Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials
by: Ning Zhao, et al.
Published: (2023-02-01)

Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era
by: Valéry Refeno, et al.
Published: (2021-08-01)

Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation
by: Jian-man Zhu, et al.
Published: (2022-04-01)

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
by: Jun-Feng Liu, et al.
Published: (2023-03-01)

Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study
by: Yanping Lin, et al.
Published: (2023-10-01)

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma
by: Hippolyte Darré, et al.
Published: (2024-03-01)

Comparative Analysis of Two Methods for the Detection of <i>EGFR</i> Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
by: Ming-Szu Hung, et al.
Published: (2019-06-01)

Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
by: Akira Nakao, et al.
Published: (2020-06-01)